Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Microbiota and Resolvins in Arthritis

Objective

The proposed work will investigate the regulation of pro-resolving lipid mediators (LM) by pathobionts and dysbiotic microbiota in rheumatoid arthritis (RA).

RA is a chronic inflammatory disease with considerable socioeconomic impact. Most treatment options carry severe side effects including immunosuppression. Recent studies found associations between RA and dysbiosis of the microbiota, with the underlying mechanisms leading to this dysbiosis remaining of interest. In addition, I recently found that in both mice during pathobiont-driven inflammatory arthritis and in plasma from patients with RA the levels of a novel family of host protective LM, termed n-3 docosapentaenoic acid-derived Resolvins (RvDn-3 DPA), were significantly altered.

The novel hypothesis of this action is that pathobionts and pathobiont-induced gut-dysbiosis trigger local inflammatory responses and impair the production of RvDn-3 DPA, resulting in exacerbation and chronicity of local inflammation.

This novel hypothesis will be addressed using a multi-pronged approach to:

1) Characterise the role of Porphyromonas gingivalis and Prevotella copri in regulating RvDn-3 DPA, local inflammation and their effects on intestinal microbiota and gut barrier function.

2) Assess the regulation of inflammatory arthritis and RvDn-3 DPA by RA patients’ microbiota.

3) Establish the protective actions of RvDn-3 DPA in pathobiont-driven inflammatory arthritis.

This will provide insights into mechanisms of pathobiont- and dysbiotic microbiota-triggered arthritic inflammation, the regulation of tissue LM profiles and identify potential novel diagnostic markers for early RA-detection. In addition, this work will establish the therapeutic potential of RvDn-3 DPA in regulating exacerbated inflammation and dysbiosis in inflammatory arthritis, providing novel therapeutic opportunities for RA treatment.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF-EF-RI - RI – Reintegration panel

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2016

See all projects funded under this call

Coordinator

QUEEN MARY UNIVERSITY OF LONDON
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 195 454,80
Address
327 MILE END ROAD
E1 4NS London
United Kingdom

See on map

Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 195 454,80
My booklet 0 0